Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, open-label, parallel-group, controlled, phase 1/2 study to evaluate the safety and surgery-sparing effect of PhageBank phage therapy in conjunction with antibiotics for patients with culture-proven chronic prosthetic joint infection who are candidates for two stage exchange arthroplasty

Next Previous
X
Search
Trial Profile

A randomized, open-label, parallel-group, controlled, phase 1/2 study to evaluate the safety and surgery-sparing effect of PhageBank phage therapy in conjunction with antibiotics for patients with culture-proven chronic prosthetic joint infection who are candidates for two stage exchange arthroplasty

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 10 Apr 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bacteriophage therapeutics-BiomX (Primary) ; Antibacterials
  • Indications Bone and joint infections
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 18 Mar 2024 According to a BiomX media release, Adaptive Phage Therapeutics has been acquired and merged into BiomX
    • 16 Feb 2021 New trial record
    • 10 Feb 2021 According to an Adaptive Phage Therapeutics media release, the company U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for the initiation of this study. The company expects to initiate this study in the first half of 2021 in collaboration with Mayo Clinic in Rochester, Minnesota. An first interim data analysis from this study is expected in the first quarter of 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top